Manufacturer
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
Contents
Idarucizumab
Indication
Specific reversal agent for dabigatran & in patients treated w/ dabigatran when rapid reversal of anticoagulant effects is required for emergency surgery/urgent procedures or life-threatening or uncontrolled bleeding.
Instruction
5 g (2 x 2.5 g/50 mL) IV as 2 consecutive infusions over 5-10 min each or as bolus inj. Bleeding recurrence/2nd emergency/urgent procedure w/ prolonged clotting time 2nd 5-g dose may be considered. Restarting antithrombotic therapy Reinitiated after 24 hr & other antithrombotic therapy (eg, LMWH) may be started at any time if clinically stable & adequate hemostasis has been achieved.
Drug interaction
Not to be mixed w/ other medicinal drugs. Not to be administered w/ other infusion in parallel via same IV access.
Malaysia
